Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

USF medical engineering professors Dr. Richard Heller and Dr. Mark Jaroszeski have spent more than three decades developing a ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...